Humstard 30/70 Injection 40IU/ml is a premixed insulin formulation containing 70% insulin isophane (NPH insulin) and 30% human insulin, designed for the management of diabetes mellitus requiring insulin therapy. This combination provides both intermediate-acting and short-acting insulin components, facilitating improved glycemic control by addressing both basal and prandial insulin requirements. The intermediate-acting insulin isophane component ensures a sustained insulin effect, typically lasting up to 18-24 hours, while the human insulin component offers rapid onset to manage postprandial glucose excursions. Humstard 30/70 Injection is indicated for adult and pediatric patients with type 1 or type 2 diabetes mellitus when diet, exercise, and oral hypoglycemic agents alone are insufficient to achieve adequate glycemic control. Administration is via subcutaneous injection, with dosing individualized based on patient needs, blood glucose monitoring, and glycemic targets. Proper rotation of injection sites is recommended to prevent lipodystrophy. Patients should be counseled on recognizing and managing hypoglycemia, a potential adverse effect. Humstard 30/70 should be stored under refrigeration and protected from freezing and excessive heat to maintain potency. This insulin preparation should be used under medical supervision with regular monitoring of blood glucose and HbA1c levels to optimize therapeutic outcomes.